Old Drug, New Rules: Where Methotrexate Fits in Modern Still’s Disease Care
A new narrative review repositions methotrexate as a complementary, steroid-sparing option in Still's disease while confirming that early interleukin-1 or ...
A new narrative review repositions methotrexate as a complementary, steroid-sparing option in Still's disease while confirming that early interleukin-1 or ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.